# Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation

> **NCT06668324** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 134 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06668324
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-15
- **Primary completion:** 2025-09-05
- **Final completion:** 2025-09-05
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06668324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06668324, "Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06668324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*